These sustained CBF changes have been associated with cognitive impairment (Hanyu et al., 2010; Leeuwis et al., 2017; Nielsen et al., 2017), and are disease specific (Abdi et al., 2012; Gao et al., 2013; Le Heron et al., 2014) that precede the other AD clinical symptoms (Hays et al., 2016). This evidence concerns the gene CEBPZ and Alzheimer disease.